Damloran Pharmaceutical (XTEH:DAML1) GF Score: 27/100 (As of Jul. 28, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTEH:DAML1 Damloran Pharmaceutical XTEH:DAML1
27 GF Score
Price IRR10,100.00
View Full Analysis

What is Damloran Pharmaceutical GF Score?

Damloran Pharmaceutical XTEH:DAML1 27 GF Score is 27 as of Jul. 28, 2026, which is at its 10-year median of 27.00. GuruFocus rates XTEH:DAML1 with a GF Score™ of 27/100.

Damloran Pharmaceutical has the GF Score of 27, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 4/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Damloran Pharmaceutical might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Damloran Pharmaceutical  (XTEH:DAML1) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Damloran Pharmaceutical GF Score Related Terms

XTEH:DAML1 vs IMNPQ: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Damloran Pharmaceutical's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Damloran Pharmaceutical GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Damloran Pharmaceutical's GF Score distribution charts can be found below:

* The bar in red indicates where Damloran Pharmaceutical's GF Score falls into.


XTEH:DAML1
27GF Score
Damloran Pharmaceutical XTEH:DAML1
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 27 mean?
Damloran Pharmaceutical (XTEH:DAML1) has a GF Score of 27 as of Jul. 28, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Damloran Pharmaceutical and its competitors. This is near median its historical median of 27.00. Over the past decade, Damloran Pharmaceutical's GF Score has ranged from 27.00 to 100.00.
Is Damloran Pharmaceutical's GF Score too high?
Damloran Pharmaceutical's current GF Score of 27 is near median its 10-year median of 27.00. Over the past 10 years, this metric has ranged from a low of 27.00 to a high of 100.00. Overall, Damloran Pharmaceutical has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Damloran Pharmaceutical's GF Score compare to IMNPQ?
Damloran Pharmaceutical's GF Score of 27 can be compared against companies in the Drug Manufacturers industry. Historically, Damloran Pharmaceutical's own GF Score has ranged from 27.00 to 100.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Damloran Pharmaceutical and its competitors. Damloran Pharmaceutical's current GF Score is 27, which is near median its own 10-year median of 27.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Damloran Pharmaceutical stock overvalued right now?
Damloran Pharmaceutical (XTEH:DAML1) has a current GF Score of 27. The current GF Score is 27, which is near median its 10-year median of 27.00. Damloran Pharmaceutical's overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Damloran Pharmaceutical (XTEH:DAML1), the current GF Score is 27 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Damloran Pharmaceutical Business Description

Address No.4, Parvin Alley, West Fatemi Avenue, Tehran, IRN
Damloran Pharmaceutical manufactures and markets livestock and poultry pharmaceuticals. The Company offers animal health products to protect and improve health and hygiene of society to treat and to enhance the quality of animals' life.
27GF Score

Get the complete analysis for XTEH:DAML1

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

IRR10,100.00
Price